- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases — Active Not Recruiting • Phase II • NCT04554914.
- A trial testing a new cell therapy (tabelecleucel) to treat diseases caused by Epstein-Barr virus infection.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases. Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma Interventions: Tabelecleucel Lead Sponsor: Pierre Fabre Medicament Planned Enrollment: 190 participants